Head of Antibody Therapy Unit National Cancer Institute
Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.
Ovarian cancer, liver cancer.